Richter Gedeon Vegyeszeti Gyar Nyrt
OTC:RGEDF
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| HU |
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
BET:RICHTER
|
1.9T HUF |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -4.5% |
| 30th Percentile | 4.8% |
| Median | 12.7% |
| 70th Percentile | 32.7% |
| Max | 60 198% |
Other Profitability Ratios
Richter Gedeon Vegyeszeti Gyar Nyrt
Glance View
Richter Gedeon Vegyeszeti Gyar Nyrt., popularly known as Gedeon Richter, traces its origins to 1901, when its founder, Gedeon Richter, established a modest pharmacy on the outskirts of Budapest. With a deep passion for innovation and a forward-thinking mindset, Richter transformed his small endeavor into Hungary's pioneering pharmaceutical company. Today, Gedeon Richter stands as a significant player in the global pharmaceutical industry, excelling in the research, development, manufacturing, and marketing of a wide array of medicinal products. The company's emphasis on in-house innovation and strategic collaborations has enabled it to carve a niche in the field of women's healthcare, biotechnology, and central nervous system therapies. The heart of Gedeon Richter's operations lies in its robust research and development capabilities. By investing heavily in scientific excellence, the company has developed a diversified portfolio that includes generic and specialty pharmaceuticals, as well as original research-driven products. The company generates revenue through a network that spans more than 100 countries, with a strong presence in Europe, the Commonwealth of Independent States, and the global markets at large. By keeping its manufacturing processes vertically integrated and maintaining a comprehensive distribution network, Gedeon Richter not only ensures efficiency and cost-effectiveness, but also consistently delivers quality products to both niche markets and mass consumers. This strategic focus on sustainable growth, combined with its commitment to providing innovative healthcare solutions, reflects the synergy of past legacy with future-focused aspirations.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Richter Gedeon Vegyeszeti Gyar Nyrt is 25.2%, which is above its 3-year median of 22.5%.
Over the last 3 years, Richter Gedeon Vegyeszeti Gyar Nyrt’s Net Margin has decreased from 32.1% to 25.2%. During this period, it reached a low of 11.6% on Sep 30, 2023 and a high of 32.1% on Sep 30, 2022.